U.S.District Court grants injunction to Amgen to prevent Sanofi + Regeneron marketing Praluent (alirocumab) in the US due to patent infringement.
Sanofi and Regeneron Pharmaceuticals, Inc. announced that they will appeal the injunction granted by the U.S. District Court for the District of Delaware preventing the marketing, selling or manufacturing of Praluent (alirocumab) in the U.S. during the term of two Amgen patents. The companies believe Amgen’s asserted patent claims are invalid and will also appeal a prior jury verdict upholding the validity of those patents. The court has delayed imposition of the injunction for 30 days to allow Sanofi and Regeneron to file a motion for a suspension (stay) of this injunction during the appeal process. Praluent continues to be available to patients at this time.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins